Bio-Thera, Dr. Reddy’s partner to commercialise BAT2206, a proposed Stelara Biosimilar, and BAT2506, a proposed Simponi Biosimilar Read more
Indian pharma companies focus on innovative research in foreign countries through dedicated entities Read more
Toripalimab can fortify Dr. Reddy’s oncology portfolio as first checkpoint inhibitor for NPC in India: GlobalData Read more